Evidence map›Paper›PMID 35360523›Full record

ArticleJHEP reports : innovation in hepatology2022

Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada.

Carla Osiowy, Ken Swidinsky, Sarah Haylock-Jacobs, Matthew D Sadler, Scott Fung, David Wong, Gerald Y Minuk, Karen E Doucette, Philip Wong, Edward Tam and 6 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Article
  6. Hepatitis Delta and Liver Disease Among People Living With Hepatitis B With or Without HIV Co-Infection in Senegal.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  7. Virological markers for clinical trials in chronic viral hepatitis.JHEP reports : innovation in hepatology · 2024
    Review
  8. Hepatitis Delta Virus and Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Hepatitis Delta Infection: A Clinical Review.Seminars in liver disease · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Carla OsiowyNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Ken SwidinskyNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Sarah Haylock-JacobsUniversity of Calgary, Calgary, AB, Canada.
Matthew D SadlerUniversity of Calgary, Calgary, AB, Canada.
Scott FungUniversity of Toronto, Toronto, ON, Canada.
David WongUniversity of Toronto, Toronto, ON, Canada.
Gerald Y MinukUniversity of Manitoba, Winnipeg, MB, Canada.
Karen E DoucetteUniversity of Alberta, Edmonton, AB, Canada.
Philip WongMcGill University, Montreal, QC, Canada.
Edward TamLAIR Centre, Vancouver, BC, Canada.
Curtis CooperUniversity of Ottawa, Ottawa, ON, Canada.
Alnoor RamjiUniversity of British Columbia, Vancouver, BC, Canada.
Mang MaUniversity of Alberta, Edmonton, AB, Canada.
Carmine NudoHôpital de la Cité-de-la-Santé, Laval, QC, Canada.
Keith TsoiMcMaster University, Hamilton, ON, Canada.
Carla S CoffinUniversity of Calgary, Calgary, AB, Canada.
University of Calgary · CAPublic Health Agency of Canada · CAUniversity of Alberta · CAUniversity of Toronto · CAMcGill University · CAMcMaster University · CAUniversity of British Columbia · CAUniversity of Manitoba · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: HDV affects 4.5-13% of chronic hepatitis B (CHB) patients globally, yet the prevalence of HDV infection in Canada is unknown. To investigate the prevalence, genotype, demographics, and clinical characteristics of HDV in Canada, we conducted a retrospective analysis of (1) HDV antibody and RNA positivity among referred specimens, and (2) a cross-sectional subset study of 135 HDV seropositive +/-RNA (HDV+) patients compared with 5,132 HBV mono-infected patients in the Canadian HBV Network. Methods: Anti-HDV IgG-positive specimens collected between 2012 and 2019 were RNA tested and the genotype determined. Patients enrolled in the Canadian HBV Network were >18 years of age and HBsAg-positive. Clinical data collected included risk factors, demographics, comorbidities, treatment, fibrosis assessment, and hepatic complications. Results: Of the referred patients, 338/7,080 (4.8%, 95% CI 4.3-5.3) were HDV seropositive, with 219/338 RNA-positive (64.8%, 95% CI 59.6-69.7). The HDV+ cohort were more likely to be born in Canada, to be White or Black/African/Caribbean than Asian, and reporting high-risk behaviours, compared with HBV mono-infected patients. Cirrhosis, complications of end-stage liver disease, and liver transplantation were significantly more frequent in the HDV+ cohort. HDV viraemia was significantly associated with elevated liver transaminases and cirrhosis. Five HDV genotypes were observed among referred patients but no association between genotype and clinical outcome was detected within the HDV+ cohort. Conclusions: Nearly 5% of the Canadian HBV referral population is HDV seropositive. HDV infection is highly associated with risk behaviours and both domestic and foreign-born patients with CHB. HDV was significantly associated with progressive liver disease highlighting the need for increased screening and surveillance of HDV in Canada. Lay summary: Evidence of HDV infection was observed in approximately 5% of Canadians who were infected with HBV referred to medical specialists. HDV-positive patients were more likely to be male, born in Canada, or White or Black/African/Caribbean compared to Asian, and to have reported high-risk activities such as injection or intranasal drug use or high-risk sexual contact compared with patients infected with only HBV. Patients infected with HDV were also more likely to suffer severe liver disease, including liver cancer, compared with HBV mono-infected patients.

Indexed as

ALT, alanine aminotransferaseAST, aspartate aminotransferasebp, base pairsCanHepB Network, Canadian HBV networkCHB, chronic HBV infectionCirrhosisEpidemiologyGenotypegt, genotypeHCC, hepatocellular carcinomaHepatitis B virusHepatitis D virusIFNα, pegylated interferon-alphaINR, international normalised ratio (prothrombin time of blood clotting)NAs, nucleos(t)ide analogue inhibitorsn, countNML, National Microbiology LaboratoryqHBsAg, quantitative HBsAgTE, transient elastography

Identifiers

PMID35360523
PMCPMC8961228
OpenAlexW4214591600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.